Please use this identifier to cite or link to this item:
|Statistics||SHARE CORE MendeleyBASE||
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis
|Authors:||Cantó, E.; Morcillo-Suárez, Carlos ; Comabella, Manuel|
|Citation:||Multiple Sclerosis 18(7): 983-990 (2012)|
|Abstract:||[Background] Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in multiple sclerosis (MS) pathogenesis.|
[Objective] The objective of this study was to investigate the role of plasma CHI3L1 in MS clinical course and disease activity and to evaluate the effect of interferon-beta (IFNβ) treatment on protein levels.
[Methods] Plasma CHI3L1 levels were determined by ELISA in 57 healthy controls (HC), 220 untreated MS patients [66 primary progressive MS patients (PPMS), 30 secondary progressive MS patients (SPMS), and 124 relapsing-remitting MS patients (RRMS), 94 during clinical remission and 30 during relapse], and 32 MS patients receiving IFNβ treatment. A polymorphism of the CHI3L1 gene, rs4950928, was genotyped in 3274 MS patients and 3483 HC.
[Results] Plasma CHI3L1 levels were significantly increased in patients with progressive forms of MS compared with RRMS patients and HC. CHI3L1 levels were similar between RRMS patients in relapse and remission. A trend towards decreased CHI3L1 levels was observed in IFNβ-treated patients. Allele C of rs4950928 was significantly associated with PPMS patients and with higher plasma CHI3L1 levels.
[Conclusions] These findings point to a role of CHI3L1 in patients with progressive forms of MS, particularly in those with PPMS. © The Author(s) 2012.
|Description:||Cantó, E. et al.|
|Publisher version (URL):||http://dx.doi.org/10.1177/1352458511433063|
|Appears in Collections:||(IPBLN) Artículos|